Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs.
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Molecule is a software platform used to decentralise intellectual property development in the biotech industry. The company was founded in 2020 by Paul Kohlhaas and Tyler Golato and is headquartered in Schaffhausen, Switzerland.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
Eleanor Health is the first addiction and mental health services provider designed to deliver long-term patient recovery outcomes and modeled on value-based care delivery and payments. Eleanor provides whole-person, comprehensive care for mental health and substance misuse through a network of outpatient clinics, virtually, and in the community and patient’s homes. Eleanor Health was founded in 2019 and headquartered in Waltham, Massachusetts.
Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine the diagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results. SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States.
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. The company was founded in 2009 and is based in Mountain View, California.
Story Health helps specialists to understand medical situations and make clinical decisions that are through virtual protocols. Story Health uses data from high-frequency sources to help clinicians understand and take action on the physiological effects of disease and therapy. It was founded in 2020 and headquartered in Saratoga, California.
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics. The company was founded in 2019 and is headquartered in San Diego, California.
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
Scitara is a global provider of laboratory-specific, cloud-based software solutions for the life sciences and other science-based industries. Their solutions are powering the digital transformation of scientific laboratories by enabling them with modern lab data connectivity infrastructure and tools to accelerate science.
Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. Leveraging its groundbreaking platform, Totus Medicines can simultaneously screen billions of drug candidates against thousands of targets, identifying superior molecules. This includes candidates for traditionally challenging, undruggable targets.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
SimBioSys is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics. The company aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Hawthorne Effect's mission is to make clinical trials accessible to everyone, everywhere. The company's proactive Visit Management System honors the relationship between sponsors and their investigators and promotes the use of shared technology to ensure protocol compliance and eliminate missing data. By enabling research teams to not only track all of their patients and thousands of data points but deploy specially trained healthcare providers (“HEROs”) to conduct visits anywhere, anytime, Hawthorne Effect ensures that no patients are “lost to follow-up.
Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Isolere Bio is a Healthcare Company.Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans. For more information, visit www.outcomes4me.com
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologists can create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
Vestaron is leading a peptide-based revolution in crop protection. The company is committed to providing growers with novel, effective, peptide-based biopesticides that address proven targets. Vestaron's peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficial, and the environment. Vestaron has earned global recognition for its work, including the inaugural 2015 Bernard Blum Award for novel biocontrol solutions, the prestigious Green Chemistry Challenge Award from the U.S. Environmental Protection Agency and the American Chemical Society Green Chemistry Institute in 2020, and Best New Biologic Product in the 2021 Crop Science Awards.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Scitara is a global provider of laboratory-specific, cloud-based software solutions for the life sciences and other science-based industries. Their solutions are powering the digital transformation of scientific laboratories by enabling them with modern lab data connectivity infrastructure and tools to accelerate science.
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Encodia provides in-depth information on cellular processes to enable personalized medicine. Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases. Encodia was established on January 1, 2015 in San Diego, California.
Octave is a clinical platform developer who is working to create a new paradigm of multiple sclerosis care by generating, analyzing, and combining data. The platform of the company provides an integrated and multi-dimensional approach to lowering total cost of care by optimizing healthcare medications and utilization, allowing pharma to optimize the entire lifecycle of drug discovery and development, clinical trials, and post-marketing with real-world evidence.
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market.
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. The company was founded in 2009 and is based in Mountain View, California.
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio was founded in 2015 by Erik Gentalen and Lena Wu and is based in Fremont, California, United States.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.
ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California.
GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use.
IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine the diagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results. SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States.
Deep Lens is a provider of a digital pathology workflow platform intended to allow pathology groups to collaborate on groundbreaking cancer research. The company's platform includes AI-powered image detection and workflow support, collaboration, cloud storage, and built-in APIs for the ingestion of third-party AI models and integration to EMR, LIMS, and other systems, helping patients, pathologists, and physicians work together to accelerate and optimize treatment. Founded in 2017, Deep Lens is headquartered in Columbus, Ohio.
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Teckro is a life science technology company that is rethinking every element of clinical research - the people, the processes, and the technologies used. By making it possible for all relevant information to be instantly accessible to every active member of a clinical trial and for the entire study teams to be connected effortlessly, Teckro is broadening the possibilities of what they can achieve. Teckro's solutions result in quicker development of drugs and treatments for the world’s most complex diseases. The company was founded in 2015 and is based in Limerick, Ireland with offices in Dublin and Nashville.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.
Intabio is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio was founded in 2015 by Erik Gentalen and Lena Wu and is based in Fremont, California, United States.
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
GALT is a developer of a microbiological technology used to help cultivate and study bacteria and other microbes. Its platform develops novel technologies that vastly increase the ability to study microbes, the single most diverse and impact group of organisms on the planet that enable scientists to uncover deeper insights into microbiome-based applications in agriculture, human health, environment, and industry. The company's mission is to transform microbiome science through high-throughput microbial isolation and cultivation array system. General Automation Lab Technologies was established in 2014 and is headquartered in San Carlos, California.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.